These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25093791)

  • 21. The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.
    Farlow MR; Grossberg G; Gauthier S; Meng X; Olin JT
    Curr Med Res Opin; 2010 Oct; 26(10):2441-7. PubMed ID: 20828359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rivastigmine exposure provided by a transdermal patch versus capsules.
    Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
    Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
    Gauthier S; Robillard A; Cohen S; Black S; Sampalis J; Colizza D; de Takacsy F; Schecter R;
    Curr Med Res Opin; 2013 Aug; 29(8):989-1000. PubMed ID: 23647369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A transdermal patch of rivastigmine (Exelon)].
    Salmon E
    Rev Med Liege; 2008 Sep; 63(9):570-1. PubMed ID: 19051514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.
    Lee JH; Sevigny J
    Alzheimer Dis Assoc Disord; 2011; 25(1):58-62. PubMed ID: 20975519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study.
    Prasher VP; Sachdeva N; Adams C; Haque MS
    Int J Geriatr Psychiatry; 2013 Feb; 28(2):219-20. PubMed ID: 23296840
    [No Abstract]   [Full Text] [Related]  

  • 28. Rivastigmine in Parkinson's disease dementia.
    Lalli S; Albanese A
    Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
    Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
    Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
    Prescrire Int; 2007 Apr; 16(88):66. PubMed ID: 17458048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.
    Amanatkar HR; Grossberg GT
    Expert Rev Neurother; 2014 Oct; 14(10):1119-25. PubMed ID: 25201245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease.
    Narasimhalu K; Effendy S; Sim CH; Lee JM; Chen I; Hia SB; Xue HL; Corrales MP; Chang HM; Wong MC; Chen CP; Tan EK
    Acta Neurol Scand; 2010 Apr; 121(4):217-24. PubMed ID: 19951274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic rationale for the rivastigmine patch.
    Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
    Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease.
    Muhlack S; Przuntek H; Müller T
    Pharmacopsychiatry; 2006 Jan; 39(1):16-9. PubMed ID: 16453249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
    Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
    Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rivastigmine patch ameliorates depression in mild AD: preliminary evidence from a 6-month open-label observational study.
    Spalletta G; Gianni W; Giubilei F; Casini AR; Sancesario G; Caltagirone C; Cravello L
    Alzheimer Dis Assoc Disord; 2013; 27(3):289-91. PubMed ID: 22760171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
    Grossberg GT; Olin JT; Somogyi M; Meng X
    Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances.
    Weiser M; Rotmensch HH; Korczyn AD; Hartman R; Cicin-Sain A; Anand R;
    Int J Geriatr Psychiatry; 2002 Apr; 17(4):343-6. PubMed ID: 11994888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.